These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27193167)

  • 21. Glutamate-induced alterations in Ca2+ signaling are modulated by mitochondrial Ca2+ handling capacity in brain slices of R6/1 transgenic mice.
    Rosenstock TR; Bertoncini CR; Teles AV; Hirata H; Fernandes MJ; Smaili SS
    Eur J Neurosci; 2010 Jul; 32(1):60-70. PubMed ID: 20608968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired PLP-dependent metabolism in brain samples from Huntington disease patients and transgenic R6/1 mice.
    Sorolla MA; Rodríguez-Colman MJ; Vall-Llaura N; Vived C; Fernández-Nogales M; Lucas JJ; Ferrer I; Cabiscol E
    Metab Brain Dis; 2016 Jun; 31(3):579-86. PubMed ID: 26666246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.
    MacGibbon GA; Hamilton LC; Crocker SF; Costain WJ; Murphy KM; Robertson HA; Denovan-Wright EM
    J Neurosci Res; 2002 Feb; 67(3):372-8. PubMed ID: 11813242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment.
    Rebec GV; Conroy SK; Barton SJ
    Neuroscience; 2006; 137(1):327-36. PubMed ID: 16257492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease.
    Kung VW; Hassam R; Morton AJ; Jones S
    Neuroscience; 2007 Jun; 146(4):1571-80. PubMed ID: 17478055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
    Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
    Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of CGS 21680, a selective adenosine A(2A) receptor agonist, on NMDA receptor function and expression in the brain of Huntington's disease mice.
    Ferrante A; Martire A; Armida M; Chiodi V; Pézzola A; Potenza RL; Domenici MR; Popoli P
    Brain Res; 2010 Apr; 1323():184-91. PubMed ID: 20138162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease.
    Traficante A; Riozzi B; Cannella M; Rampello L; Squitieri F; Battaglia G
    Neuroreport; 2007 Dec; 18(18):1997-2000. PubMed ID: 18007201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain Diffusivity and Structural Changes in the R6/2 Mouse Model of Huntington Disease.
    Vorisek I; Syka M; Vargova L
    J Neurosci Res; 2017 Jul; 95(7):1474-1484. PubMed ID: 27726161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.
    Sathyasaikumar KV; Stachowski EK; Amori L; Guidetti P; Muchowski PJ; Schwarcz R
    J Neurochem; 2010 Jun; 113(6):1416-25. PubMed ID: 20236387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.
    Johnson MA; Rajan V; Miller CE; Wightman RM
    J Neurochem; 2006 May; 97(3):737-46. PubMed ID: 16573654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
    Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
    Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice.
    Oliveira JM; Jekabsons MB; Chen S; Lin A; Rego AC; Gonçalves J; Ellerby LM; Nicholls DG
    J Neurochem; 2007 Apr; 101(1):241-9. PubMed ID: 17394466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.
    Leuti A; Laurenti D; Giampà C; Montagna E; Dato C; Anzilotti S; Melone MA; Bernardi G; Fusco FR
    Neurobiol Dis; 2013 Apr; 52():104-16. PubMed ID: 23220622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow.
    Gianfriddo M; Melani A; Turchi D; Giovannini MG; Pedata F
    Neurobiol Dis; 2004 Oct; 17(1):77-88. PubMed ID: 15350968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease.
    Cho KJ; Lee BI; Cheon SY; Kim HW; Kim HJ; Kim GW
    Neuroscience; 2009 Nov; 163(4):1128-34. PubMed ID: 19646509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low stability of Huntington muscle mitochondria against Ca2+ in R6/2 mice.
    Gizatullina ZZ; Lindenberg KS; Harjes P; Chen Y; Kosinski CM; Landwehrmeyer BG; Ludolph AC; Striggow F; Zierz S; Gellerich FN
    Ann Neurol; 2006 Feb; 59(2):407-11. PubMed ID: 16437579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. White Adipose Tissue Browning in the R6/2 Mouse Model of Huntington's Disease.
    McCourt AC; Jakobsson L; Larsson S; Holm C; Piel S; Elmér E; Björkqvist M
    PLoS One; 2016; 11(8):e0159870. PubMed ID: 27486903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
    Zourlidou A; Gidalevitz T; Kristiansen M; Landles C; Woodman B; Wells DJ; Latchman DS; de Belleroche J; Tabrizi SJ; Morimoto RI; Bates GP
    Hum Mol Genet; 2007 May; 16(9):1078-90. PubMed ID: 17360721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.